These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
506 related articles for article (PubMed ID: 34452531)
1. Peptide Platform as a Powerful Tool in the Fight against COVID-19. Murdocca M; Citro G; Romeo I; Lupia A; Miersch S; Amadio B; Bonomo A; Rossi A; Sidhu SS; Pandolfi PP; Alcaro S; Sangiuolo FC; Novelli G Viruses; 2021 Aug; 13(8):. PubMed ID: 34452531 [TBL] [Abstract][Full Text] [Related]
2. Plant-Produced Glycosylated and In Vivo Deglycosylated Receptor Binding Domain Proteins of SARS-CoV-2 Induce Potent Neutralizing Responses in Mice. Mamedov T; Yuksel D; Ilgın M; Gurbuzaslan I; Gulec B; Yetiskin H; Uygut MA; Islam Pavel ST; Ozdarendeli A; Mammadova G; Say D; Hasanova G Viruses; 2021 Aug; 13(8):. PubMed ID: 34452461 [TBL] [Abstract][Full Text] [Related]
3. Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants. Jeong BS; Cha JS; Hwang I; Kim U; Adolf-Bryfogle J; Coventry B; Cho HS; Kim KD; Oh BH MAbs; 2022; 14(1):2021601. PubMed ID: 35030983 [TBL] [Abstract][Full Text] [Related]
4. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438 [TBL] [Abstract][Full Text] [Related]
6. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260 [TBL] [Abstract][Full Text] [Related]
7. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines. Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287 [TBL] [Abstract][Full Text] [Related]
9. Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice. Sun S; He L; Zhao Z; Gu H; Fang X; Wang T; Yang X; Chen S; Deng Y; Li J; Zhao J; Li L; Li X; He P; Li G; Li H; Zhao Y; Gao C; Lang X; Wang X; Fei G; Li Y; Geng S; Gao Y; Wei W; Hu Z; Han G; Sun Y Cell Mol Immunol; 2021 Apr; 18(4):1070-1073. PubMed ID: 33731916 [No Abstract] [Full Text] [Related]
14. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109 [TBL] [Abstract][Full Text] [Related]
15. Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. McCallum M; Walls AC; Sprouse KR; Bowen JE; Rosen LE; Dang HV; De Marco A; Franko N; Tilles SW; Logue J; Miranda MC; Ahlrichs M; Carter L; Snell G; Pizzuto MS; Chu HY; Van Voorhis WC; Corti D; Veesler D Science; 2021 Dec; 374(6575):1621-1626. PubMed ID: 34751595 [TBL] [Abstract][Full Text] [Related]
16. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry. Ge J; Wang R; Ju B; Zhang Q; Sun J; Chen P; Zhang S; Tian Y; Shan S; Cheng L; Zhou B; Song S; Zhao J; Wang H; Shi X; Ding Q; Liu L; Zhao J; Zhang Z; Wang X; Zhang L Nat Commun; 2021 Jan; 12(1):250. PubMed ID: 33431856 [TBL] [Abstract][Full Text] [Related]
17. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions. Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP mBio; 2021 Mar; 12(2):. PubMed ID: 33785634 [TBL] [Abstract][Full Text] [Related]
18. Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency. Mariotti S; Capocefalo A; Chiantore MV; Iacobino A; Teloni R; De Angelis ML; Gallinaro A; Pirillo MF; Borghi M; Canitano A; Michelini Z; Baggieri M; Marchi A; Bucci P; McKay PF; Acchioni C; Sandini S; Sgarbanti M; Tosini F; Di Virgilio A; Venturi G; Marino F; Esposito V; Di Bonito P; Magurano F; Cara A; Negri D; Nisini R Front Immunol; 2021; 12():750386. PubMed ID: 34764961 [TBL] [Abstract][Full Text] [Related]
19. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants. Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425 [TBL] [Abstract][Full Text] [Related]
20. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Walls AC; Fiala B; Schäfer A; Wrenn S; Pham MN; Murphy M; Tse LV; Shehata L; O'Connor MA; Chen C; Navarro MJ; Miranda MC; Pettie D; Ravichandran R; Kraft JC; Ogohara C; Palser A; Chalk S; Lee EC; Guerriero K; Kepl E; Chow CM; Sydeman C; Hodge EA; Brown B; Fuller JT; Dinnon KH; Gralinski LE; Leist SR; Gully KL; Lewis TB; Guttman M; Chu HY; Lee KK; Fuller DH; Baric RS; Kellam P; Carter L; Pepper M; Sheahan TP; Veesler D; King NP Cell; 2020 Nov; 183(5):1367-1382.e17. PubMed ID: 33160446 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]